These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37197461)

  • 1. Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition.
    Borgini M; Wipf P
    ACS Med Chem Lett; 2023 May; 14(5):652-657. PubMed ID: 37197461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
    Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
    ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
    J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
    Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
    Bhute VJ; Ma Y; Bao X; Palecek SP
    Sci Rep; 2016 Nov; 6():36061. PubMed ID: 27811964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
    Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA damaging revolution.
    Cetin B; Wabl CA; Gumusay O
    Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the functional aspects of poly(ADP-ribose) polymerase-1 (PARP-1) in mitochondrial homeostasis in Dictyostelium discoideum.
    Kadam A; Jubin T; Roychowdhury R; Garg A; Parmar N; Palit SP; Begum R
    Biol Cell; 2020 Aug; 112(8):222-237. PubMed ID: 32324907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    McCann KE
    Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
    Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
    Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.